MacroGenics (NASDAQ: MGNX) revenue
MacroGenics reported revenue of $149.5m for fiscal 2025, 0.3% less than in fiscal 2024 ($150.0m). Since fiscal 2016 its revenue has grown by 62.7%, an average growth of 5.6% a year.
MacroGenics's best year of the last 10 was fiscal 2017. The biggest drop was in fiscal 2018, −61.9%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $149.5m | −0.3% | −$72.8m | −48.7% |
| 2024 | $150.0m | +155.3% | −$110.6m | −73.7% |
| 2023 | $58.7m | −61.3% | −$168.2m | −286.4% |
| 2022 | $151.9m | +96.2% | −$121.4m | −79.9% |
| 2021 | $77.4m | −26.2% | −$202.8m | −261.9% |
| 2020 | $104.9m | +63.4% | −$131.1m | −125.0% |
| 2019 | $64.2m | +6.8% | −$177.2m | −276.0% |
| 2018 | $60.1m | −61.9% | −$171.2m | −284.8% |
| 2017 | $157.7m | +71.7% | −$22.1m | −14.0% |
| 2016 | $91.9m | — | −$60.0m | −65.3% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
MacroGenics revenue compared with its sector
By revenue for its latest fiscal year, MacroGenics ranks 263rd of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; MacroGenics, −0.3%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 261st | Heron Therapeutics | $154.9m | 7.4% |
| 262nd | AirSculpt Technologies | $151.8m | −15.8% |
| 263rd | MacroGenics | $149.5m | −0.3% |
| 264th | Grail | $147.2m | 17.2% |
| 265th | Karyopharm Therapeutics | $146.1m | 0.6% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of MacroGenics
- How much revenue did MacroGenics make in fiscal 2025?
- MacroGenics reported revenue of $149.5m for fiscal 2025, compared with $150.0m in fiscal 2024.
- How much has the revenue of MacroGenics grown?
- Between fiscal 2016 and fiscal 2025 it went from $91.9m to $149.5m: 62.7% more, an average growth of 5.6% a year.
- What was the best year for revenue at MacroGenics?
- Of its last 10 fiscal years, fiscal 2017, with $157.7m.
- Where does MacroGenics rank in its sector by revenue?
- It ranks 263rd of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for MacroGenics come from?
- From the annual report (Form 10-K) that MacroGenics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that MacroGenics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on MacroGenics: the MacroGenics page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.